During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
How to Select First-Line Immunotherapy for Metastatic NSCLC: PD-L1, Disease Burden, and Co-Mutations
Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer. Selecting first-line ...
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has ...
New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options ...
Rusfertide (Mimrylo) significantly improved hematocrit control and reduced the need for therapeutic phlebotomy in patients ...
Vojnic is director of neuro-oncology at Rutgers Cancer Institute and system leader for neuro-oncology at RWJBarnabas Health.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET ...
Swiecicki, MD, of the University of Michigan Rogel Cancer Center, characterizes the safety and tolerability of subcutaneous ...
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone ...
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...
Al-Ola Abdallah, MD, discusses IMiD-based holding therapy before leukapheresis and its safety in patients with myeloma receiving CAR T-cell therapy. Five myeloma experts share their top takeaways from ...
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results